# Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

> **NCT01238237** · PHASE1 · COMPLETED · sponsor: **Northwell Health** · enrollment: 15 (actual)

## Conditions studied

- Glioblastoma Multiforme (GBM)
- ANAPLASTIC ASTROCYTOMA (AOA)
- GBM
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** Superselective Intraarterial Cerebral Infusion of Cetuximab

## Key facts

- **NCT ID:** NCT01238237
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238237, "Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01238237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*